Prismatic Bio is building an automation platform for biology's hardest assays, aiming to enhance patient access to new and hard-to-scale therapies. The company focuses on automating complex biological workflows that currently limit the scalability of advanced treatments. Prismatic Bio is currently engaging with partners and early-access users as it develops its platform.
Funding
Funding not disclosed
Founders
Product
Problem
Many advanced therapies rely on complex biological assays that are difficult to automate and scale, creating bottlenecks in development and manufacturing. These hard-to-scale processes limit patient access to new treatments and slow the path from research to clinical application.
Solution
Prismatic Bio is developing an automation platform specifically designed to tackle biology's most challenging assays. By automating these complex workflows, the platform aims to remove key bottlenecks in therapy development and production. This approach is intended to make new and hard-to-scale therapies more accessible to patients by streamlining the biological processes that currently hinder their widespread availability. The company is currently building the platform and engaging with potential partners and early adopters to shape its development.
Target Audience
Prismatic Bio's primary customers are biotech and pharmaceutical companies developing advanced therapies that depend on complex, hard-to-scale biological assays, as well as research organizations seeking to automate challenging experimental workflows.
Features
- Automation platform engineered for high-complexity biological assays that are difficult to scale with existing tools
- Focus on workflows associated with new and emerging therapies, addressing a critical gap in current biotech infrastructure
- Designed to reduce manual intervention and variability in assay processes, improving reproducibility and throughput
- Early-stage platform development informed by direct engagement with potential partners and early-access users